Literature DB >> 2505226

The action of flecainide acetate and its enantiomers on mammalian non-myelinated nerve fibres.

L Lie-A-Huen1, J van den Akker, A den Hertog, D K Meijer.   

Abstract

The effects of flecainide acetate racemate and its two enantiomers on voltage-operated sodium and potassium channels and on the sodium pump activity of non-myelinated fibres of the guinea-pig vagus nerve were studied with the sucrose-gap method. The racemic mixture as well as the R enantiomer and S enantiomer in a concentration range of 3 x 10(-5)-3 x 10(-4) M caused suppression of the compound action potential, a diminished propagation velocity and a reduction of the post-tetanic potential (PTH), which was also observed with lidocaine. There was no significant difference in the effect caused by the enantiomers separately. The R enantiomer tended to evoke a stronger effect compared with the S enantiomer. However, the magnitude of the action is concentration-dependent. At a concentration less than 10(-4) M the action of the racemate was stronger than an equimolar concentration of the enantiomers. The activity of the sodium pump, defined by the time constant of post-tetanic potential decay, was affected at a concentration of 10(-4) M of the racemate, in contrast to lidocaine. The racemate and both enantiomers of flecainide acetate possess a similar local anaesthetic action, as reflected by the inhibition of voltage-operated sodium channels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505226     DOI: 10.1007/bf02110256

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  8 in total

1.  On the electrogenic sodium pump in mammalian non-myelinated nerve fibres and its activation by various external cations.

Authors:  H P Rang; J M Ritchie
Journal:  J Physiol       Date:  1968-05       Impact factor: 5.182

2.  Some further observations on the electrogenic sodium pump in non-myelinated nerve fibres.

Authors:  A den Hertog
Journal:  J Physiol       Date:  1973-06       Impact factor: 5.182

3.  Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.

Authors:  J Morganroth; L N Horowitz
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

4.  Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.

Authors:  A J Camm; K J Hellestrand; A W Nathan; R S Bexton
Journal:  Drugs       Date:  1985       Impact factor: 9.546

5.  The proarrhythmic effects of flecainide.

Authors:  A W Nathan; K J Hellestrand; R S Bexton; R A Spurrell; A J Camm
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  The effect of some new aminopyridines on mammalian non-myelinated nerve fibres.

Authors:  A Den Hertog; J Pielkenrood; P Biessels; S Agoston
Journal:  Eur J Pharmacol       Date:  1983-10-28       Impact factor: 4.432

7.  Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers.

Authors:  E H Banitt; J R Schmid; R A Newmark
Journal:  J Med Chem       Date:  1986-02       Impact factor: 7.446

Review 8.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

  8 in total
  2 in total

1.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.